CONCANNON CHRISTOPHER R 4

4 · MARKETAXESS HOLDINGS INC · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

MarketAxess (MKTX) CEO Christopher Concannon Receives Awards, Surrenders Shares

What Happened

Christopher R. Concannon, CEO of MarketAxess Holdings (MKTX), received multiple equity awards and also surrendered shares to cover tax withholding. On Feb 13, 2026 he was credited with 1,696 shares (award). On Feb 15, 2026 he was credited with 6,588 shares (restricted stock units) and a derivative award of 21,736 shares (stock options/derivative). To satisfy tax withholding obligations, he surrendered 866 shares on Feb 15 and an additional 1,750 shares on Feb 15 at $179.36 per share, resulting in dispositions totaling $155,326 and $313,880 respectively (combined ~$469,206). All awards show $0.00 per-share acquisition price (grants).

Key Details

Transaction dates and prices:
- 2026-02-13: Award of 1,696 shares (acquired at $0.00) — related to PSU certification.
- 2026-02-15: Award of 6,588 restricted stock units (acquired at $0.00).
- 2026-02-15: Award of 21,736 derivative securities (acquired at $0.00).
- 2026-02-15: Surrender of 866 shares at $179.36 to satisfy tax withholding ($155,326).
- 2026-02-15: Surrender of 1,750 shares at $179.36 to satisfy tax withholding ($313,880).
Shares owned after transaction: Not stated in the filing summary provided.
Footnotes of note:
- F1: Compensation committee certified performance metrics for PSUs granted Feb 15, 2023 (triggering vesting/certification).
- F2 & F4: The 866 and 1,750 share disposals represent share surrenders to the company to satisfy tax-withholding on vested PSUs/RSUs (not open-market sales).
- F3: 6,588 shares represent a grant of restricted stock units with vesting 34% on 2/15/27, 33% on 2/15/28 and 33% on 2/15/29.
- F5: The 21,736 derivative award relates to stock options with the same 34%/33%/33% vesting schedule.
Filing date: Form 4 filed 2026-02-17 (transactions occurred 2026-02-13 and 2026-02-15).

Context

The "disposals" here are tax-withholding surrenders (routine) rather than open-market sales; they do not necessarily indicate a change in the CEO's view of the company.
The award entries are grants (RSUs, PSUs and derivatives) and therefore represent compensation/long-term incentive rather than purchases.
For the option/derivative grant, vesting is multi-year (2027–2029), so the derivative award is subject to time- and performance-based vesting per the footnotes.

Form 4

Period: 2026-02-13

DirectorChief Executive Officer

Transactions

Award
Common Stock, par value $0.003 per share
[F1]
2026-02-13+1,696→ 49,977 total
Tax Payment
Common Stock, par value $0.003 per share
[F2]
2026-02-15$179.36/sh−866$155,326→ 49,111 total
Award
Common Stock, par value $0.003 per share
[F3]
2026-02-15+6,588→ 55,699 total
Tax Payment
Common Stock, par value $0.003 per share
[F4]
2026-02-15$179.36/sh−1,750$313,880→ 53,949 total
Award
Stock Option (right to buy)
[F5]
2026-02-15+21,736→ 21,736 total
Exercise: $179.36Exp: 2032-02-15→ Common Stock (21,736 underlying)

Footnotes (5)

[F1]On February 13, 2026, the Compensation and Talent Committee of the Board of Directors of the Issuer certified the performance metrics relating to the performance stock units granted to the Reporting Person on February 15, 2023.
[F2]Represents the surrender of shares to the Company to satisfy the Reporting Person's tax withholding obligation upon the vesting of the performance stock units.
[F3]Represents a grant of restricted stock units pursuant to the Company's 2020 Equity Incentive Plan. The restricted stock units shall vest 34% on February 15, 2027, 33% on February 15, 2028, and 33% on February 15, 2029.
[F4]Represents the surrender of shares to the Company to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units previously granted to the Reporting Person.
[F5]The stock options shall vest 34% on February 15, 2027, 33% on February 15, 2028, and 33% on February 15, 2029.

Signature

/s/ Patrick Wilson as Attorney-in-Fact for Christopher R. Concannon|2026-02-17

1 file